

DEVELOPMENT IN REGENSBURG

Guest contribution from Dr. Thomas Diefenthal

Current BioPark Annual Report 2022

The companies in the cluster from the fields of biotechnology, pharmaceuticals, medical engineering, diagnostics, analytics and the healthcare industry were able to continue to significantly expand their business in Eastern Bavaria in the post-Corona period and have increased their staff substantially. The total number of companies in the cluster increased slightly compared to the previous year to 66 companies (+3). The total number of employees increased strongly from 4,504 to 5,340 (+16%).



© BioPark Regensburg

The BioPark is currently fully booked. The technology and start-up center accommodates 35 leaseholders with almost 676 employees in its three buildings on a gross area of 18,000 m². These include start-up companies, university and non-university institutions, companies from Germany and abroad, as well as service providers and our own daycare center.

Healthcare Regensburg – managed by BioPark

Today, a total of 21,600 employees with social security were working in the health sector in the Regensburg region. That is a good 33.8% more than in the 2011 census. At 55%, the largest proportion is employed in five hospitals. 80% of the employees work in the urban area and 20% in the rural district. There are currently 831 companies in the health sector in the Regensburg

area, 60% of them in the city and 40% in the district. These generated sales of EUR 2.7 billion in the last year, which is almost twice as much as in 2011 with a rate of increase of 92.9% and corresponds to an annual growth rate of 7.6%.

The RCI becomes a Leibniz Institute in Regensburg

The Regensburg Center for Interventional Immunology (RCI) was founded in 2010 as a central institution of the University of Regensburg to bundle all university research areas working on the development of new immunotherapies. In 2022 the RCI was included in the federal-state funding of the Leibniz Association. The new LIT (Leibniz-Institute for Immunotherapy) focuses on translational immunology in the fields of cancer immunotherapy, chronic inflammation and autoimmunity.

Regensburg clusters bundle AI expertise

In Regensburg - a high-tech and science location where artificial intelligence shows itself in all its facets - BioPark Regensburg has been working together with the Mobility & Logistics clusters, the IT Security Cluster and the Sensor Technology Cluster in the joint AI initiative AIR (Artificial Intelligence Regensburg). AIR is a clear commitment from the regional networks for "their" region to jointly deliver a future-oriented, regional development concept that actively involves and mobilizes their respective stakeholders. The aim is to better network the stakeholders in the clusters and thus enable an optimized transfer of knowledge and technology. Industry affiliations play

a subordinate role, especially in cross-sectional technologies such as artificial intelligence.

BioPark Jump Accelerator gets started in Regensburg

To further expand start-up support, BioPark Jump has launched on its own premises and with many supporters at BioPark Regensburg. The project will be funded by the Bavarian Ministry of Economic Affairs for the next three years. With BioPark Jump, a previously non-existent contact point has been created specifically for those interested in founding a company in the healthcare sector in the region. It supports prospective start-ups in the early founding phases on their way into the healthcare market, from the idea and the development of a functioning business model to team building and raising funds to commercialization. BioPark Jump will work closely with the existing start-up networks, the BioPark Brain 8 Network, the BioPark Innovation Award, the technology and transfer facilities of the universities and regional industrial partners and the TechBase (digitalization).

BioPark Regensburg
www.biopark-regensburg.de

BioPark Jump
www.biopark-jump.de

BioPark Award
www.biopark-innovationspreis.de

DR. THOMAS DIEFENTHAL

is Managing Director of BioPark Regensburg GmbH and Vice President of the German Association of Innovation, Technology and Business Incubation Centres (BVIZ) in Berlin.



© BioPark Regensburg GmbH, Elisabeth Wiesner